Endotrophin and Fibroinflammatory Disease

Kim Henriksen, Federica Genovese, Alexander Reese-Petersen, Laurent P Audoly, Kai Sun, Morten A Karsdal, Philipp E Scherer
Endocrine Reviews, First published online December 13, 2023, bnad036
https://doi.org/10.1210/endrev/bnad036

Abstract

Our overview covers several key areas related to recent results obtained for collagen type VI and endotrophin (ETP). An introduction to the history of ETP, including how it was identified, how it is released, and its function and potential receptors. An introduction to the collagen family, with a focus on what differentiates collagen type VI from an evolutionary standpoint. An overview of collagen type VI, the 6 individual chains (COL6A1, A2, A3, A4, A5, and A6), their differences and similarities, as well as their expression profiles and function. A detailed analysis of COL6A3, including the cleaved product endotrophin, and what separates it from the other 5 collagen 6 molecules, including its suggested function based on insights gained from knockout and gain of function mouse models. The pathology of ETP. What leads to its presence and release and what are the consequences thereof? Functional implications of circulating ETP. Here we review the data with the functional roles of ETP in mind. We propose that ETP is a mediator for fibrotic (or fibroinflammatory) disorders. Based on what we know about ETP, we have to consider it as a target for the treatment of fibrotic (or fibroinflammatory) disorders. What segment(s) of the patient population would most dramatically respond to an ETP-targeted intervention? How can we find the population that would profit most from an intervention? We aim to present a broad overview over the ETP field at large, providing an assessment of where the future research efforts need to be placed to tap into the vast potential of ETP, both as a marker and as a target in different diseases.

You may also like...